Topic: mergers and acquisitions
Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.
The actions are part of the biotech’s ongoing efforts to seek a way out of its R&D-triggered troubles.
The Federal Trade Commission is requesting additional information from Boston Scientific and BTG ahead of their proposed $4.2 billion deal.
Johnson & Johnson is diving deeper into robotic surgery with a $3.4 billion deal for Auris Health, designer of endoscopes aimed at lung cancer.
Trice Medical plans to acquire S.E.G-Way Orthopaedics to offer both diagnostic and surgical solutions for minimally invasive orthopedic procedures.
Welsh CRO Simbec-Orion was acquired by U.K.-based private equity firm CBPE Capital for an undisclosed price.
WIRB-Copernicus Group acquires Velos eResearch, a clinical trial management solutions provider, for an undisclosed price.
Abcam acquires California’s Calico Biolabs for an undisclosed price.
The deal adds digital tools for conditions such as depression, chronic pain and opioid addiction to Livongo’s repertoire.
For $10 million upfront, Aldeyra is picking up a drug for proliferative vitreoretinopathy, which will enter the clinic in 2019.